The use of this GIP/GLP-1 dual agonist in individuals with type 2 diabetes has shown superiority with respect to HbA1c lowering, body-weight reduction, improvement in lipid profile and reduction of arterial blood pressure, as compared with placebo, semaglutide or insulin [91, 92]. Here, GIP is linked to type 2 diabetes mellitus.